The RADAR Study: Week 48 Safety and Efficacy of RAltegravir Combined with Boosted DARunavir Compared to Tenofovir/Emtricitabine Combined with Boosted Darunavir in Antiretroviral-Naive Patients. Impact on Bone Health

BACKGROUND: NRTI-sparing regimens may avoid long-term mitochondrial, bone and renal toxicities and maintain viral suppression. METHODS: In the RADAR study, 85 antiretroviral-naïve HIV-infected patients were randomized to receive either raltegravir (RAL) (n = 42) or tenofovir/emtricitabine (TDF/FTC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Bedimo, Roger J., Drechsler, Henning, Jain, Mamta, Cutrell, James, Zhang, Song, Li, Xilong, Farukhi, Irfan, Castanon, Rosinda, Tebas, Pablo, Maalouf, Naim M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149560/
https://www.ncbi.nlm.nih.gov/pubmed/25170938
http://dx.doi.org/10.1371/journal.pone.0106221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149560/
https://www.ncbi.nlm.nih.gov/pubmed/25170938
http://dx.doi.org/10.1371/journal.pone.0106221

Ejemplares similares